Simtra Biopharma Solutions Capabilities Update August 2026: CPHI Special Edition

Sterile injectable manufacturing continues to face mounting pressures, from capacity constraints and supply chain uncertainty to the growing complexity of biologics, ADCs, and personalized therapies. In this presentation, Rich Kennedy of Simtra Biopharma Solutions shares how direct customer feedback has shaped the company's investment strategy and expanded its ability to support evolving market needs.

The session explores key trends influencing sterile manufacturing, including demand for flexible capacity, regional production capabilities, and specialized expertise for high-potency compounds. Kennedy outlines significant investments in new fill-finish infrastructure across the United States and Europe, highlighting expanded syringe, vial, lyophilization, and high-potent manufacturing capabilities designed to support products from clinical development through commercialization.

Attendees will gain insight into how manufacturers are addressing industry challenges through scalable facilities, advanced filling technologies, and customized production environments. The discussion also examines the importance of quality, operational flexibility, and long-term capacity planning in helping drug developers navigate increasingly complex development and commercialization pathways.